David C. Oxley

Director/Board Member at TB Biosciences, Inc.

Health Technology

Health Services

Profile

David C.
Oxley is currently a Non-Executive Director at TB Biosciences, Inc. He previously held the position of Executive VP-Worldwide Sales & Marketing at Trinity Biotech Plc and Vice President-Emerging Market Sales at Plus Therapeutics, Inc. He will also serve as the President-International at Exopharm Ltd.
from 2021 to 2023.

David C. Oxley active positions

Companies	Position	Start
TB Biosciences, Inc. TB Biosciences, Inc. Medical/Nursing ServicesHealth Services TB Biosciences, Inc. operates as a early stage development medical diagnostics company which develops a rapid point-of-care tuberculosis tests. It uses key peptides to detect antibodies in patients with active tuberculosis derived from the genome of the tuberculosis organism, thus offering a completely new approach to testing. The firm is using an array of patented peptides developed and exclusively licensed from the New York university school of medicine. The company was founded by Daniel Malamud, Susan Zolla-Pazner, Suman Laal, R. Sam Niedbala and William Abrams in May 2013 and is headquartered in Bethlehem, PA.	Director/Board Member	2013-07-31

All active positions of David C. Oxley

Former positions of David C. Oxley

Companies	Position	End
EXOPHARM	President	2022-12-31
TRINITY BIOTECH PLC	Sales & Marketing	-
PLUS THERAPEUTICS, INC.	Sales & Marketing	-

See the detail of David C. Oxley's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of David C. Oxley's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
TRINITY BIOTECH PLC	Health Technology
PLUS THERAPEUTICS, INC.	Health Technology

Private companies	2
TB Biosciences, Inc. TB Biosciences, Inc. Medical/Nursing ServicesHealth Services TB Biosciences, Inc. operates as a early stage development medical diagnostics company which develops a rapid point-of-care tuberculosis tests. It uses key peptides to detect antibodies in patients with active tuberculosis derived from the genome of the tuberculosis organism, thus offering a completely new approach to testing. The firm is using an array of patented peptides developed and exclusively licensed from the New York university school of medicine. The company was founded by Daniel Malamud, Susan Zolla-Pazner, Suman Laal, R. Sam Niedbala and William Abrams in May 2013 and is headquartered in Bethlehem, PA.	Health Services
Exopharm Ltd. Exopharm Ltd. Pharmaceuticals: MajorHealth Technology Exopharm Ltd. engages in the research and development of biopharmaceutical drugs. The company was founded by Ian Dixon and Gregor Lichtfuss in 2013 and is headquartered in Camberwell, Australia.	Health Technology